Last reviewed · How we verify
Placebo equivalent to amoxycillin
A placebo formulation designed to mimic amoxicillin for use in clinical trials or research studies without providing active antibiotic effect.
Placebo equivalent to amoxycillin, marketed by Menzies School of Health Research, holds a unique position in the therapeutic landscape as a non-active comparator. The key composition patent is set to expire in 2028, which may provide a period of exclusivity and stability in the market. However, the lack of a defined mechanism and primary indication poses a significant risk in terms of regulatory scrutiny and market acceptance.
At a glance
| Generic name | Placebo equivalent to amoxycillin |
|---|---|
| Sponsor | Menzies School of Health Research |
| Modality | Small molecule |
| Therapeutic area | Research/Clinical Trial Tool |
| Phase | FDA-approved |
Mechanism of action
This is an inert placebo preparation manufactured to match the appearance, taste, and administration characteristics of amoxicillin (a beta-lactam antibiotic) for blinded clinical trial purposes. It contains no active pharmaceutical ingredient and therefore produces no antimicrobial effect, allowing researchers to isolate and measure placebo response in study populations.
Approved indications
- Control arm in clinical trials evaluating amoxicillin efficacy
Common side effects
Key clinical trials
- Hospitalised Pneumonia With Extended Treatment (HOPE) Study (PHASE4)
- ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 (PHASE3)
- Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers (PHASE2)
- Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia (PHASE3)
- Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia (PHASE3)
- Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: